GlaxoSmithKline sees better signs for lung drugs after tough 2014

LONDON, Feb 4 (Reuters) - GlaxoSmithKline said on Wednesday it expected to start to regain market share in respiratory medicine after weak demand for lung drug Advair again hurt fourth-quarter sales, capping a rough year for Britain's top drugmaker.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.